Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

BACKGROUND: Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in patients who do not respond to steroids. We assessed the effect of early SIT intro...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Sbeih, Hamzah, Ali, Faisal S., Wang, Xuemei, Mallepally, Niharika, Chen, Ellie, Altan, Mehmet, Bresalier, Robert S., Charabaty, Aline, Dadu, Ramona, Jazaeri, Amir, Lashner, Bret, Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444537/
https://www.ncbi.nlm.nih.gov/pubmed/30940209
http://dx.doi.org/10.1186/s40425-019-0577-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444537/
https://www.ncbi.nlm.nih.gov/pubmed/30940209
http://dx.doi.org/10.1186/s40425-019-0577-1

Ejemplares similares